- Home
- DHY vs MNPR Comparison
DHY vs MNPR Comparison
Compare DHY & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- MNPR
- Stock Information
- Founded
- DHY 1998
- MNPR 2014
- Country
- DHY United States
- MNPR United States
- Employees
- DHY N/A
- MNPR N/A
- Industry
- DHY Finance/Investors Services
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- DHY Finance
- MNPR Health Care
- Exchange
- DHY Nasdaq
- MNPR Nasdaq
- Market Cap
- DHY 212.4M
- MNPR 249.5M
- IPO Year
- DHY N/A
- MNPR 2019
- Fundamental
- Price
- DHY $2.05
- MNPR $30.01
- Analyst Decision
- DHY
- MNPR Strong Buy
- Analyst Count
- DHY 0
- MNPR 5
- Target Price
- DHY N/A
- MNPR $59.50
- AVG Volume (30 Days)
- DHY 569.1K
- MNPR 20.8K
- Earning Date
- DHY 01-01-0001
- MNPR 05-13-2025
- Dividend Yield
- DHY 9.10%
- MNPR N/A
- EPS Growth
- DHY N/A
- MNPR N/A
- EPS
- DHY N/A
- MNPR N/A
- Revenue
- DHY N/A
- MNPR N/A
- Revenue This Year
- DHY N/A
- MNPR N/A
- Revenue Next Year
- DHY N/A
- MNPR N/A
- P/E Ratio
- DHY N/A
- MNPR N/A
- Revenue Growth
- DHY N/A
- MNPR N/A
- 52 Week Low
- DHY $1.77
- MNPR $1.72
- 52 Week High
- DHY $2.08
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- DHY 51.40
- MNPR 34.22
- Support Level
- DHY $1.92
- MNPR $28.40
- Resistance Level
- DHY $2.00
- MNPR $36.82
- Average True Range (ATR)
- DHY 0.02
- MNPR 3.29
- MACD
- DHY 0.00
- MNPR -0.79
- Stochastic Oscillator
- DHY 50.00
- MNPR 13.50
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.